Diligence memo · auto-generated · as of July 2, 2026
Inviragen, Inc.
Inviragen, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Inviragen, Inc. operates in Biotechnology, based in FORT COLLINS.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Inviragen, Inc. has raised $32M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $15M on 2009-09-22.
Most recent recorded round closed around 2009-09-22.
Valuation (modeled)modeled
Provath models Inviragen, Inc. at approximately $608M (range $31M–$2.3B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.68× the median modeled value of Series B Biotechnology companies in 2007–2009 (21 peers) — value vs value, same stage and era. Within the normal band (68% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 16.8 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 2.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 75% of Biotechnology peers (4293 compared).
Modeled value ranks above 85% of those peers.
Closest niche peers: Ion Torrent Systems Inc, PhotoThera Inc, Taligen Therapeutics Inc, Atritech Inc, Barosense Inc.
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.